Creative Planning Buys 322 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Creative Planning increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 8.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,935 shares of the biotechnology company’s stock after purchasing an additional 322 shares during the quarter. Creative Planning’s holdings in United Therapeutics were worth $1,410,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in UTHR. SG Americas Securities LLC increased its holdings in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after acquiring an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares in the last quarter. Comerica Bank raised its position in shares of United Therapeutics by 5.9% during the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares during the period. Tri Locum Partners LP purchased a new position in shares of United Therapeutics during the 2nd quarter valued at $15,959,000. Finally, QRG Capital Management Inc. boosted its holdings in United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after buying an additional 1,692 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $361.40 on Thursday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $377.03. The stock’s 50-day moving average price is $354.34 and its 200-day moving average price is $315.28. The stock has a market capitalization of $16.03 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 1.27 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the prior year, the business posted $5.24 earnings per share. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $324.73, for a total value of $1,169,028.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $42,214.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $324.73, for a total transaction of $1,169,028.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $42,214.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the transaction, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 107,012 shares of company stock worth $36,767,286. Corporate insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent analyst reports. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Oppenheimer boosted their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. UBS Group raised their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $361.33.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.